Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces $525 Million Accretive Core-Area Saskatchewan Asset Acquisition (click to learn more) Safe Supply Streaming Portfolio Company Safety Strips, Provides Corporate Update (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Regen BioPharma Inc RGBP

Regen BioPharma Inc. is a biotechnology company. The Company is engaged on the immunology and immunotherapy space. The Company is focused on novel technologies through pre-clinical and Phase I/ II clinical trials. It is involved on mRNA and small molecule therapies for treating cancer and autoimmune disorders. It is also developing products treating blood disorders using small molecules and... see more

OTCPK:RGBP - Post Discussion

Regen BioPharma Inc > Regen BioPharma, Inc. CEO Outlines Future Steps in CAR T Pro
View:
Post by averagepennies on Nov 14, 2023 10:16am

Regen BioPharma, Inc. CEO Outlines Future Steps in CAR T Pro

SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of its DuraCAR CAR T-cell therapeutic (https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-experiments-validating-its-proprietary-car-t-cell-therapy-301623585.html). This program is designed to create chimeric antigen T-cells that silence the gene for NR2F6. As part of the development of this program, it was discovered that NR2F6 mRNA was greatly increased, thus identifying new, unexpected and potentially extremely useful findings in developing cell therapy treatments for autoimmune disorders https://www.prnewswire.com/news-releases/studies-on-regen-biopharma-incs-duracar-indicate-potential-suppression-of-autoimmunity-company-retains-contract-research-organization-to-conduct-additional-confirmatory-studies-301931365.html.

 

https://www.prnewswire.com/news-releases/regen-biopharma-inc-ceo-outlines-future-steps-in-car-t-program-301986597.html

Be the first to comment on this post
Regen BioPharma Inc